Open Orphan, Chris Bailey on 3 Big Caps & John Meyer on 3 Resource Companies
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan, Chris Bailey on 3 Big Caps & John Meyer on 3 Resource Companies
Cathal Friel, Executive Chairman, Open Orphan #ORPH discusses their £2.5m Influenza challenge study contract win with a US biotechnology company.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility. hVIVO's challenge studies require healthy volunteers to take part, volunteers are recruited through FluCamp, learn more at www.FluCamp.com. The hVIVO facility offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development. Reliable laboratory analysis underpinned by scientific expertise is essential when processing and analysing clinical samples. Robust quality processes support our team of scientists in the delivery of submission ready data.
Chris Bailey founder of Financial Orbit covers news from the following companies:
Sainsbury's #SBRY
Astrazeneca #AZN
Autotrader #AUTO
(Interview starts at 8 minutes 34 seconds)
John Meyer, Mining analyst and partner at SP Angel talks about:
Eurasia Mining #EUA
Rainbow Rare Earth #RBW
SolGold #SOLG
(Interview starts at 33 minutes 17 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.